Janux Therapeutics earnings were -$114.5M for the trailing 12 months ending Mar 31, 2026, with N/A growth year over year. The latest JANX earnings report on Mar 31, 2026 announced Q1 2026 earnings of -$24.4M, down 23.7% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, JANX reported annual earnings of -$113.6M, with 64.7% growth.
What were Janux Therapeutics's earnings last quarter?
Janux Therapeutics (NASDAQ: JANX) reported Q1 2026 earnings per share (EPS) of -$0.39, up 2.63% year over year. Total JANX earnings for the quarter were -$24.36 million. In the same quarter last year, Janux Therapeutics's earnings per share (EPS) was -$0.38.
As of the last Janux Therapeutics earnings report, Janux Therapeutics is currently losing money. Janux Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2026 was -$114.48 million, a 47.25% increase year over year.
What was JANX's earnings growth in the past year?
As of Janux Therapeutics's earnings date in Q2 2026, Janux Therapeutics's earnings has grown year over year. JANX earnings in the past year totalled -$114.48 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.